相关实验视频
Updated: Jun 8, 2026

09:40
Magnetic Adjustment of Afterload in Engineered Heart Tissues
Published on: May 5, 2020
6.3K
心血管血管血管学与干预协会的病因学,管理和结果 B 阶段心脏性休克心脏性休克
Chirag Mehta1, Phinnara Has2, Aryan Mehta3,4
1Department of Medicine (C.M., I.V., B.O., A. Shin, V.C., S.C., D.D.P., A. Sweeting, R.T.), Warren Alpert Medical School of Brown University, Providence, RI.
Circulation. Heart failure
|February 19, 2026
概括
四分之一的心血管血管血管学会和干预协会 (SCAI) B心脏性休克患者的心血管休克状况恶化. 急性损伤和利尿剂耐药性预测这些患者的结果会更差.
科学领域:
- 心脏病学 心脏病学
- 临界护理医学 临界护理医学
- 临床研究 临床研究
背景情况:
- 关于心血管血管血管学与干预协会 (SCAI) B心血管性休克病因,管理和结果的数据有限.
- 在成人患者中,SCAI B心脏性休克的特征是低血压或低输血.
研究的目的:
- 评估SCAI B心脏性休克的病因,管理和结果.
- 为了确定SCAI B心脏性休克患者临床恶化的预测因素.
主要方法:
- 在2017-2022年期间,对500名SCAI B心脏性休克患者进行了回顾性研究.
- 定义的SCAI B心脏性休克为低血压 (静脉压≤90/平均≤65mm Hg) 或低输液 (乳酸盐2-5mEq/L),不包括心脏骤停和循环支持.
- 使用多变量分析和混合效应回归来确定复合终点的预测因素,包括转移到更高的护理,SCAI阶段升级或住院死亡率.
主要成果:
- 最常见的病因是心力衰竭 (37%),心律失常 (23%) 和急性心肌梗塞 (13%).
- 四分之一的患者 (135/500) 经历了临床恶化.
- 恶化的独立预测因素包括急性损伤 (aOR 2.17) 和利尿剂耐药性 (aOR 9.55). 患有孤立低血压的患者比患有孤立低血压的患者有更糟糕的结果.
结论:
- 四分之一的SCAI B心脏性休克患者经历了临床恶化.
- 24小时内急性损伤和利尿剂耐药性是临床恶化的独立预测因素.
- 这些发现突出了监测和管理SCAI B心脏性休克患者的关键因素.
相关概念视频
Blood Pressure Imbalances and Circulatory Shock
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...

